Abstract PR014: preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment - Jänne, P A; Bigot, F; Papadopoulos, K (Mol Cancer Ther, 2023)